

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of: Jacques DUMAS et al. :

Serial No.: 09/776,935 : Group Art Unit: 1617

Filed: December 22, 1998 : Examiner: Bahar, M.

For: INHIBITION OF p38 KINASE USING ARYL AND HETEROARYL
SUBSTITUTED HETEROCYCLIC UREAS

MAY 18 2004

DECLARATION OF PRIOR INVENTION UNDER 37 CFR § 1.131

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

I, the undersigned, hereby declare that I am a co-inventor of the subject matter of claims 1-30 within the above application and that the subject matter of claims 1-30 was reduced to practice before November 3, 1997, as indicated in the attached document entitled "p38 active Phenylpyrazole 971029.xis," which is dated before November 3, 1997.

All dates and data have been redacted from the document and compounds which are not listed in the tables within the above identified application have also been redacted from this document.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,









William Scott

Date

DRAFTED BY [redacted]

** TOTAL PAGE.02 **









A	
1	CHEMISTRY
2	36-9480 
3	36-9481 
4	36-9570 (not 36-9507) 
5	36-9576 (not 36-9513) 
6	36-9584 (not 36-9521) 
7	36-9719 
8	36-9720 
9	36-9721 








p38 active Phenylpyrazole 971029.xls

A	
1	CHEMISTRY
10	36-9722
11	36-9932
12	33
13	36-9934
14	36-9935
15	36-9936
16	36-9937
17	37-9530





p38 active Phenylpyrazole 971029.xls

A	
1 CHEMISTRY	
18	37-9531 
19	37-9532 
20	
21	
22	37-9535 
23	37-9693 
24	37-9695 
25	37-9697 

p38 active Phenylpyrazole 971029.xls

A	
1 CHEMISTRY	
26	37-9699 
27	37-9701 
28	37-9772 (not 37-9785) 
29	37-9786 
30	37-9787 
31	37-9788 
32	37-9943 

p38 active Phenylpyrazole 971029.xls

A	
1 CHEMISTRY	
33	39-9074 
34	39-9077 
35	39-9080 
36	39-9082 
37	39-9084 